JP2024534062A5 - - Google Patents
Info
- Publication number
- JP2024534062A5 JP2024534062A5 JP2024509374A JP2024509374A JP2024534062A5 JP 2024534062 A5 JP2024534062 A5 JP 2024534062A5 JP 2024509374 A JP2024509374 A JP 2024509374A JP 2024509374 A JP2024509374 A JP 2024509374A JP 2024534062 A5 JP2024534062 A5 JP 2024534062A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163234001P | 2021-08-17 | 2021-08-17 | |
| US63/234,001 | 2021-08-17 | ||
| US202163275714P | 2021-11-04 | 2021-11-04 | |
| US63/275,714 | 2021-11-04 | ||
| PCT/US2022/040478 WO2023023065A1 (en) | 2021-08-17 | 2022-08-16 | Inducible cytokine prodrug and pd-1/pd-l1 combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024534062A JP2024534062A (ja) | 2024-09-18 |
| JP2024534062A5 true JP2024534062A5 (https=) | 2025-08-25 |
| JPWO2023023065A5 JPWO2023023065A5 (https=) | 2025-08-25 |
Family
ID=85239682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024509374A Pending JP2024534062A (ja) | 2021-08-17 | 2022-08-16 | 誘導性サイトカインプロドラッグ及びｐｄ－１／ｐｄ－ｌ１併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240216505A1 (https=) |
| EP (1) | EP4387649A4 (https=) |
| JP (1) | JP2024534062A (https=) |
| AU (1) | AU2022331261A1 (https=) |
| CA (1) | CA3228964A1 (https=) |
| TW (1) | TW202320838A (https=) |
| WO (1) | WO2023023065A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| WO2024248490A1 (ko) * | 2023-05-30 | 2024-12-05 | 아주대학교산학협력단 | Pd-l1을 표적으로 하는 키메라 항원 수용체 및 이를 발현하는 t 세포 치료제 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080167238A1 (en) * | 2001-12-21 | 2008-07-10 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| CA3100005A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| US20210130430A1 (en) * | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| BR112022009110A2 (pt) * | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
-
2022
- 2022-08-16 JP JP2024509374A patent/JP2024534062A/ja active Pending
- 2022-08-16 WO PCT/US2022/040478 patent/WO2023023065A1/en not_active Ceased
- 2022-08-16 AU AU2022331261A patent/AU2022331261A1/en active Pending
- 2022-08-16 CA CA3228964A patent/CA3228964A1/en active Pending
- 2022-08-16 EP EP22859046.9A patent/EP4387649A4/en active Pending
- 2022-08-17 TW TW111131042A patent/TW202320838A/zh unknown
-
2024
- 2024-02-13 US US18/440,816 patent/US20240216505A1/en active Pending